NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. The medical research company had revenue of $104.70 million for the quarter, compared to analyst estimates of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. NeoGenomics's revenue was up 51.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

7 analysts have issued 1-year price targets for NeoGenomics' shares. Their forecasts range from $14.00 to $35.00. On average, they anticipate NeoGenomics' share price to reach $24.67 in the next year. This suggests that the stock has a possible downside of 25.2%. View Analyst Price Targets for NeoGenomics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News stories about NEO stock have trended very positive recently, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NeoGenomics earned a news impact score of 3.9 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in December. As of December 31st, there was short interest totalling 6,920,000 shares, an increase of 9.1% from the December 15th total of 6,340,000 shares. Based on an average daily trading volume, of 678,300 shares, the short-interest ratio is presently 10.2 days. Approximately 7.0% of the shares of the stock are short sold. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Cochlear (COH), Varian Medical Systems (VAR), Bausch Health Companies (BHC), DENTSPLY SIRONA (XRAY), Steris (STE), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Universal Health Services (UHS), Fisher & Paykel Healthcare (FPH), EXACT Sciences (EXAS), Elanco Animal Health (ELAN), Insulet (PODD), West Pharmaceutical Services (WST), Teva Pharmaceutical Industries (TEVA) and Bio-Rad Laboratories (BIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), Marvell Technology Group (MRVL), NVIDIA (NVDA), Micron Technology (MU), Netflix (NFLX), AbbVie (ABBV), Canopy Growth (CGC), AT&T (T), Advanced Micro Devices (AMD) and Amarin (AMRN).

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.35%), Norris Perne & French LLP MI (0.33%), Falcon Point Capital LLC (0.08%), State of Alaska Department of Revenue (0.08%), Louisiana State Employees Retirement System (0.03%) and HWG Holdings LP (0.01%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC, Louisiana State Employees Retirement System, Summit Creek Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was bought by a variety of institutional investors in the last quarter, including HWG Holdings LP, Miles Capital Inc., OLD National Bancorp IN, Sciencast Management LP, Norris Perne & French LLP MI, Exchange Traded Concepts LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $32.99.

NeoGenomics has a market capitalization of $3.44 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]